Skip to main content
UnicornBurnBETA
Evaluate a dealFeaturesMethodologyPricing
// sign inStart free →
Evaluate a dealFeaturesMethodologyPricing// sign inStart free trial →

// PLATFORM

FeaturesEvaluate a dealMethodologyPricingAPI

// COMPANY

AboutChangelogSecurityContact

// EXPLORE

AutopsiesRankingsInvestorsShare your story
© 2026 UnicornBurn
PrivacyTermsData RightsAccessibility
← All autopsies·China·Fintech
// startup autopsy

Lufax

China's largest P2P lender. Regulators eliminated P2P. -95% from peak.

regulation
Founded2011
Closed2023
CountryChina
SectorFintech
RaisedPublic (NYSE)
FounderJi Guangheng

// the model, blind

Evaluating only Lufax’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.

Full Analysis

Free · no account needed

Documented cause

Lufax was China's largest P2P lending and wealth management platform, backed by Ping An. It IPO'd on NYSE in 2020 at $39B valuation. China's P2P lending crackdown — which eliminated the entire industry — forced Lufax to completely restructure its business model. By 2023 the company had transitioned to a guarantee-model lender and its stock had fallen 95%+ from peak.

Lesson

“Building a business in a regulatory category that the Chinese government has explicitly identified for elimination is not a risk — it is a timeline. When China eliminates P2P lending, every P2P lender's business model disappears simultaneously.”

FAQ

Why did Lufax decline?

Lufax, China's largest P2P lender that IPO'd at $39B, saw its stock fall 95%+ from peak after China's regulatory crackdown eliminated the P2P lending industry entirely. The company was forced to completely restructure its business model.

// MORE FINTECH FAILURES
Wirecard
Fintech
compare →
Silicon Valley Bank
Fintech
Sudden Collapse
compare →
LendingClub (2016 crisis)
Fintech
compare →
Wealthfront (acquisition collapse)
Fintech
compare →
// engine intelligence on Lufax
Tier 1 · instant unlock🔒 free account
Loading engine analysis…
Tier 2 · the productAnalyst · €149/mo

What you see retrospectively on Lufax, applied predictively to your companies:

  • →Cross-reference this pattern against your live portfolio
  • →Alerts when a company you track starts matching this profile
  • →Export the IC-ready risk brief (PDF)
See Analyst plan →Evaluate a deal →

5,032 documented autopsies · 85.9% Top-3 cause match. How we measure accuracy →

← PrevMoguEcommerce
XLinkedInClaim this autopsy·Report error
¿Te ha sido útil?